ERBB2 and cholangiocarcinoma: Moreover, the expanding realm of targeted therapy in CCA, driven by genetic profiling and gene mutations such as FGFR2, IDH1, IDH2, NTRK, BRAF, and HER2, is revolutionizing personalized treatment approaches.